Fayerweather Charles Buys New Position in Becton Dickinson and Co (NYSE:BDX)

Fayerweather Charles bought a new stake in shares of Becton Dickinson and Co (NYSE:BDX) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 1,561 shares of the medical instruments supplier’s stock, valued at approximately $393,000.

A number of other hedge funds have also recently made changes to their positions in the stock. FMR LLC boosted its stake in Becton Dickinson and by 5.0% during the first quarter. FMR LLC now owns 17,835,000 shares of the medical instruments supplier’s stock valued at $4,453,934,000 after buying an additional 842,590 shares in the last quarter. Ronna Sue Cohen boosted its stake in Becton Dickinson and by 24,129.0% during the first quarter. Ronna Sue Cohen now owns 5,734,031 shares of the medical instruments supplier’s stock valued at $5,734,000 after buying an additional 5,710,365 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Becton Dickinson and by 10.4% during the first quarter. JPMorgan Chase & Co. now owns 4,418,870 shares of the medical instruments supplier’s stock valued at $1,103,526,000 after buying an additional 416,459 shares in the last quarter. Fundsmith LLP boosted its position in shares of Becton Dickinson and by 0.9% in the 1st quarter. Fundsmith LLP now owns 3,771,159 shares of the medical instruments supplier’s stock valued at $941,772,000 after purchasing an additional 35,453 shares during the period. Finally, Northern Trust Corp boosted its position in shares of Becton Dickinson and by 0.7% in the 1st quarter. Northern Trust Corp now owns 3,223,811 shares of the medical instruments supplier’s stock valued at $805,082,000 after purchasing an additional 23,645 shares during the period. 84.80% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts recently weighed in on BDX shares. Wells Fargo & Co decreased their price target on Becton Dickinson and from $280.00 to $265.00 and set an “outperform” rating for the company in a research report on Monday, May 13th. Morgan Stanley increased their price target on Becton Dickinson and from $250.00 to $261.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 16th. BMO Capital Markets decreased their price target on Becton Dickinson and from $272.00 to $270.00 and set a “market perform” rating for the company in a research report on Friday, May 10th. Raymond James increased their price target on Becton Dickinson and from $265.00 to $288.00 and gave the company a “strong-buy” rating in a research report on Friday, June 28th. Finally, KeyCorp reiterated an “overweight” rating and issued a $262.00 price target (down previously from $273.00) on shares of Becton Dickinson and in a research report on Friday, May 10th. Five investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Becton Dickinson and has a consensus rating of “Buy” and a consensus target price of $265.00.

Shares of NYSE:BDX traded down $3.66 during midday trading on Friday, reaching $248.69. The company had a trading volume of 1,166,959 shares, compared to its average volume of 816,174. The company has a debt-to-equity ratio of 0.82, a quick ratio of 0.59 and a current ratio of 0.96. Becton Dickinson and Co has a 1-year low of $208.62 and a 1-year high of $265.87. The company has a market capitalization of $68.07 billion, a price-to-earnings ratio of 22.59, a price-to-earnings-growth ratio of 1.87 and a beta of 1.11. The company has a fifty day simple moving average of $250.17.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.57 by $0.02. The firm had revenue of $4.20 billion during the quarter, compared to the consensus estimate of $4.25 billion. Becton Dickinson and had a return on equity of 14.58% and a net margin of 5.88%. The business’s revenue for the quarter was down .6% on a year-over-year basis. During the same period in the prior year, the business earned $2.65 EPS. As a group, sell-side analysts forecast that Becton Dickinson and Co will post 11.68 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 9th will be paid a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 1.24%. The ex-dividend date is Friday, September 6th. Becton Dickinson and’s dividend payout ratio is currently 27.97%.

In related news, EVP Patrick Kaltenbach sold 191 shares of the stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $241.03, for a total value of $46,036.73. Following the completion of the sale, the executive vice president now directly owns 19,072 shares of the company’s stock, valued at approximately $4,596,924.16. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Betty D. Larson sold 1,700 shares of the stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $224.97, for a total value of $382,449.00. Following the completion of the sale, the executive vice president now directly owns 11,493 shares of the company’s stock, valued at $2,585,580.21. The disclosure for this sale can be found here. Over the last three months, insiders sold 21,154 shares of company stock valued at $4,955,775. Company insiders own 0.12% of the company’s stock.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Read More: What is a Special Dividend?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.